One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Torgrim Tandstad,Olof Ståhl,Ulf Håkansson,Olav Dahl,Hege Sagstuen Haugnes,O. Klepp,Carl W. Langberg,Anna Laurell,Jan Oldenburg,Arne Solberg,Karin Söderström,Eva Cavallin-Ståhl,U. Stierner,R Wahlquist,Najme Wall,Gabriella Cohn-Cedermark

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

2014

Torgrim Tandstad
Olof Ståhl
Ulf Håkansson
Olav Dahl
Hege Sagstuen Haugnes
O. Klepp
Carl W. Langberg
Anna Laurell
Jan Oldenburg
Arne Solberg
Karin Söderström
Eva Cavallin-Ståhl
U. Stierner
R Wahlquist
Najme Wall
Gabriella Cohn-Cedermark

The SWENOTECA group treated 517 clinical stage I nonseminoma patients with one course of adjuvant BEP in a prospective study. The median follow-up is 7.9 years. One course of adjuvant BEP reduced t ...

Keywords:

Prospective cohort study
Pharmaceutical Adjuvants
Adjuvant
Pathology
Medicine
Testicular cancer
neoplasm staging
Neoplasm Recurrence
Chemotherapy
adjuvant chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations